Cytospire Therapeutics is a shortlisted nominee at the 2025 Cancer Research Horizons Innovation and Entrepreneurship Awards

Cytospire Therapeutics is delighted to have been shortlisted for the ‘New Start-Up of the Year’ award at this year’s Cancer Research Horizons Innovation and Entrepreneurship Awards 2025.

This award celebrates new UK-based start-ups that are fast-tracking scientific breakthroughs to develop new treatments, diagnostics and/or medical devices for the benefit of cancer patients.

Being shortlisted for this award is great recognition for the team at Cytospire and highlights the advances we have made in developing the next generation of immune cell engagers as treatments for cancer and autoimmune disease.

In addition, Natalie Mount, our Co-Founder and CEO, has been nominated for the ‘Woman Entrepreneur of the Year’ award. This award celebrates the outstanding achievements of women entrepreneurs who have established, or are actively working towards establishing, a business or a transformative partnership to accelerate scientific discoveries into novel treatments, diagnostics and/or medical devices for the benefit of people affected by cancer.  We’re delighted to see this recognition of Natalie and the other shortlisted nominees.

About Cytospire Therapeutics

Cytospire is developing an innovative portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells.  Our core technology allows binding and activation of both tissue/tumor and blood resident gamma delta T cells. This opens a path to safer and more efficacious targeting of well-validated antigens that are intractable to CD3 T cell engagers due to toxicity. There are broad opportunities for Cytospire’s gamma delta T cell engagers in solid and haematological malignancies, as well as in autoimmune disease. For more information, visit www.cytospire.com

Contact

Andrew Fadden
Chief Business Officer
info@cytospiretx.com